Incannex September 2021 Quarterly Activities Report and Appendix 4C

Highlights:
• Phase 2a psilocybin-assisted therapy for Generalised Anxiety Disorder clinical trial has received approval to proceed from the Monash University Human Research Ethics Committee
• The FDA in pre-IND meeting confirmed that the therapeutic strategy for the development of a psilocybin-assisted therapy for Generalised Anxiety Disorder is appropriate
• Incannex received ethics approval to commence an open label extension to the phase 2b clinical trial for IHL-42X in patients with Obstructive Sleep Apnoea
• IHL filed an International Patent Application for the use of IHL-42X for treatment of obstructive sleep apnoea. The International Search Report and Opinion considered key claims to be both novel and inventive.
• IHL commenced a phase 1 clinical trial to assess IHL-675A soft gel capsules in healthy volunteers
• Incannex announced the public filing of a registration statement on Form F-1 with the US Securities and Exchange Commission as it pursues listing on the Nasdaq
• Incannex completes option exercise program to raise A$17.66M; including A$8.20M from Chief Medical Officer, Dr Sud Agarwal